Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(9):674-675; doi:10.1093/jnci/93.9.674
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 9, 674-675, May 2, 2001
© 2001 Oxford University Press

NEWS

Barrett’s Esophagus: Major Issues Uncertain and Unsolved

Mike Miller

Although physicians reported large increases in gastroesophageal reflux disease (GERD) and Barrett’s esophagus in the 1990s, a series of recent workshops have concluded that there is insufficient information to make firm treatment, surveillance, or other recommendations about the diseases.

Most scientists in the field concur on how cancer evolves in the esophagus. The commonly accepted pathway for progression from normal squamous epithelium to cancer starts with reflux-associated esophageal damage (GERD), then advances to intestinal metaplasia (early Barrett’s esophagus), followed by low- and high-grade dysplasia (Barrett’s esophagus), and finally adenocarcinoma.

"We need to conduct studies to nail down the incidence and prevalence of Barrett’s [esophagus] and GERD, identify etiologies and risk factors for both . . . [Full Text of this Article]

Treating Symptoms


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?